Skip to content
Inciteful Med

Survivorship & Daily Management: Living with MG

Last updated:

Most people with Myasthenia Gravis can achieve a stable life by tracking symptoms with the MG-ADL scale and avoiding triggers like heat, stress, and certain medications. Long-term goals include reaching a state where symptoms no longer interfere with daily activities.

Key Takeaways

  • • Tracking your symptoms using the MG-ADL scale helps you know exactly when to contact your neurologist.
  • • Environmental and physical factors like heat, fever, stress, and infections can trigger a temporary worsening of symptoms.
  • • Certain antibiotics, magnesium products, and anesthetics can block neuromuscular transmission and cause a crisis.
  • • Healthy pregnancies are entirely possible but require careful medication planning with your care team.
  • • With modern treatment, the majority of patients can achieve Minimal Manifestation Status or Complete Stable Remission.

Living with Myasthenia Gravis (MG) is a long-term journey, but for the majority of patients, it is a journey toward stability [1][2]. With modern treatment, most people can achieve a state where the disease no longer dictates their daily activities [3][4].

Tracking Your “Safety Factor” at Home

In MG, the “safety factor”—your body’s ability to ensure a nerve signal successfully triggers a muscle contraction—is reduced [5][6]. You can track this safety factor at home using the MG-ADL (Activities of Daily Living) scale. This is an 8-item questionnaire that measures how your symptoms affect everyday life, such as talking, chewing, and breathing [7][8].

  • The 2-Point Rule: A change of 2 points or more on your total MG-ADL score is considered a “clinically important” change [9][10]. If your score increases by 2 points, it’s a clear signal to contact your neurologist [10].

Managing Triggers

Because your muscle-nerve communication is sensitive, certain environmental and physical factors can cause a temporary “flare” [11][5]:

  • Heat and Fever: High temperatures (like hot weather or a fever) reduce the safety factor of your neuromuscular junction [5][6]. Practical strategies like using cooling vests, taking lukewarm showers, and promptly treating fevers with acetaminophen can help maintain your strength [5].
  • Stress: Emotional or physical stress can lower your threshold for symptoms [12]. Developing a mindfulness practice or a stress-management plan is a vital part of long-term care [13].
  • Infections: Systemic inflammation from infections (like the flu, COVID-19, or a UTI) can exacerbate MG symptoms [14][11]. Staying up-to-date on vaccines and seeking early treatment for infections is critical to preventing a crisis [14].

⚠️ Red Flag Medications

Certain medications can interfere with your muscle-nerve connection and may even trigger a myasthenic crisis [15][16]. Always check with your neurologist before starting any new medication. It is highly recommended that you wear a Medical Alert Bracelet stating you have MG so emergency responders are aware of these risks.

Medication Category High-Risk Examples Why They Are Dangerous
Antibiotics Fluoroquinolones (Ciprofloxacin, Levaquin), Aminoglycosides (Gentamicin) Directly block neuromuscular transmission [15][16].
Magnesium (Hidden Sources) IV Magnesium, Epsom salts, certain antacids (Milk of Magnesia), laxatives Magnesium inhibits the release of the chemical signals needed for muscle contraction [15][17].
Heart / Blood Pressure Certain Beta-Blockers Can worsen MG weakness and breathing [15][18].
Anesthetics General anesthesia (neuromuscular blockers) Can cause prolonged paralysis after surgery. (Note: Local anesthesia, like novocaine at the dentist, is generally safe but should be discussed with your provider) [15][19].

Family Planning and Pregnancy

Because MG often affects women of childbearing age, family planning is a critical part of survivorship [20]. It is absolutely possible to have a healthy pregnancy with MG, but it requires careful planning with a high-risk OB/GYN and your neurologist [20][21].

  • Medication Safety: As mentioned in Treatment Options, certain drugs like Mycophenolate Mofetil (MMF) and Methotrexate cause severe birth defects and must be stopped well before conception [22][20].
  • Transient Neonatal MG: Roughly 10-20% of babies born to mothers with MG may experience temporary muscle weakness (such as a weak cry or poor suckling) caused by the mother’s antibodies crossing the placenta [20][21]. This condition is temporary and resolves completely within a few weeks as the mother’s antibodies clear from the baby’s system [20].

The Long-Term Goal: MMS and CSR

As you manage your MG, you and your doctor will work toward two key milestones:

  1. Minimal Manifestation Status (MMS): This means you have no symptoms that interfere with your daily life, though you may still need a small amount of medication [3][4]. Between 50% and 86% of generalized MG patients achieve this state [23][4].
  2. Complete Stable Remission (CSR): This is the “gold standard”—no symptoms for at least one year while taking no MG-specific medication [3][4]. CSR is most common in patients who have had a thymectomy [24][25].

While the “diagnostic odyssey” and the need for chronic monitoring can cause anxiety, remember that MG is one of the most treatable neurological conditions today. By monitoring your symptoms, avoiding triggers, and working closely with your care team, you can expect to live a full and productive life.

Frequently Asked Questions

How can I track my Myasthenia Gravis symptoms at home?
You can track your symptoms using the MG-ADL scale, an 8-item questionnaire that measures how the disease affects daily activities like talking and breathing. An increase of 2 or more points is a clear signal that you should contact your neurologist.
What medications should I avoid if I have Myasthenia Gravis?
Certain antibiotics, hidden sources of magnesium like Epsom salts, specific blood pressure medications, and general anesthetics can severely worsen your symptoms. Always consult your neurologist before starting any new prescription or over-the-counter drug.
Can heat make my Myasthenia Gravis worse?
Yes, high temperatures from hot weather, hot showers, or a fever can temporarily worsen your muscle-nerve communication and trigger a flare. Using cooling vests, taking lukewarm showers, and treating fevers promptly can help maintain your strength.
Is it safe to get pregnant if I have Myasthenia Gravis?
Yes, it is possible to have a healthy pregnancy, but it requires careful planning with your neurologist and a high-risk OB/GYN. Some common medications used for the condition must be stopped well before conception due to the risk of severe birth defects.
What is Minimal Manifestation Status?
Minimal Manifestation Status means you have no symptoms interfering with your daily life, even though you may still take a small amount of medication. This is a highly achievable long-term goal for the majority of patients.

Questions for Your Doctor

  • • What is my current MG-ADL score, and at what point should I call the office if my score increases?
  • • Are there specific 'Red Flag' medications on my chart that all my other doctors (dentist, PCP, specialists) can see?
  • • Can you help me develop a specific plan for managing infections like the flu or COVID-19 to prevent a crisis?
  • • Is 'Minimal Manifestation Status' (MMS) a realistic goal for my specific subtype of MG?
  • • How often should we repeat my chest imaging to monitor my thymus or surgical site?

Questions for You

  • • Have you practiced using the MG-ADL scale at home to see how your symptoms fluctuate throughout the week?
  • • What are your most common triggers—is it heat, a long day at work, or emotional stress?
  • • Do you feel confident in explaining your 'Red Flag' medications to a healthcare provider in an emergency?
  • • How are you managing the emotional stress or 'scan anxiety' that often comes with a chronic condition like MG?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Recent advances in understanding and managing myasthenia gravis.

    Jordan A, Freimer M

    F1000Research 2018; (7()) doi:10.12688/f1000research.15973.1.

    PMID: 30443340
  2. 2

    Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

    Wolfe GI, Kaminski HJ, Aban IB, et al.

    The Lancet. Neurology 2019; (18(3)):259-268 doi:10.1016/S1474-4422(18)30392-2.

    PMID: 30692052
  3. 3

    Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting.

    Shivaram S, Nagappa M, Varghese N, et al.

    Neurology India 2022; (70(5)):1931-1941 doi:10.4103/0028-3886.359277.

    PMID: 36352590
  4. 4

    Characteristics of myasthenia gravis in elderly patients: a retrospective study.

    Li Y, Dong X, Li Z, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(4)):2775-2783 doi:10.1007/s10072-021-05599-z.

    PMID: 34677704
  5. 5

    Neuromuscular synapse electrophysiology in myasthenia gravis animal models.

    Plomp JJ, Huijbers MGM, Verschuuren JJGM

    Annals of the New York Academy of Sciences 2018; (1412(1)):146-153 doi:10.1111/nyas.13507.

    PMID: 29068559
  6. 6

    Structure and function of the neuromuscular junction in health and myasthenia gravis.

    Plomp JJ, Webster RG

    International review of neurobiology 2025; (182()):1-19 doi:10.1016/bs.irn.2025.04.036.

    PMID: 40675731
  7. 7

    Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets.

    Janssen MF, Dewilde S, Wolfe GI, et al.

    Journal of the neurological sciences 2024; (463()):123135 doi:10.1016/j.jns.2024.123135.

    PMID: 39068745
  8. 8

    Physician- and self-assessed myasthenia gravis activities of daily living score.

    Lee HL, Min JH, Seok JM, et al.

    Muscle & nerve 2018; (57(3)):419-422 doi:10.1002/mus.25764.

    PMID: 28796382
  9. 9

    Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

    Habib AA, Benatar M, Vu T, et al.

    European journal of neurology 2024; (31(12)):e16490 doi:10.1111/ene.16490.

    PMID: 39373062
  10. 10

    Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.

    Zhu W, Chen Y, Tian C, et al.

    Journal of neurology 2025; (272(9)):622 doi:10.1007/s00415-025-13367-8.

    PMID: 40921886
  11. 11

    [Myasthenia gravis].

    Schodrowski J, Seipelt M, Adibi-Sedeh I, et al.

    Der Internist 2016; (57(4)):349-61 doi:10.1007/s00108-016-0035-9.

    PMID: 27000188
  12. 12

    Defective autophagy and autophagy activators in myasthenia gravis: a rare entity and unusual scenario.

    Al-Kuraishy HM, Sulaiman GM, Jabir MS, et al.

    Autophagy 2024; (20(7)):1473-1482 doi:10.1080/15548627.2024.2315893.

    PMID: 38346408
  13. 13

    A Review of Psychiatric Comorbidity in Myasthenia Gravis.

    Law C, Flaherty CV, Bandyopadhyay S

    Cureus 2020; (12(7)):e9184 doi:10.7759/cureus.9184.

    PMID: 32802619
  14. 14

    A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation.

    Song J, Zhao R, Yan C, et al.

    Frontiers in immunology 2022; (13()):746068 doi:10.3389/fimmu.2022.746068.

    PMID: 35154091
  15. 15

    Myasthenia Gravis: A Rare Neurologic Complication of Immune Checkpoint Inhibitor Therapy.

    Shames Y, Errante M, Keteku NP

    Journal of the advanced practitioner in oncology 2022; (13(2)):151-157 doi:10.6004/jadpro.2022.13.2.6.

    PMID: 35369395
  16. 16

    Myasthenia Gravis and its Association With Thyroid Diseases.

    Amin S, Aung M, Gandhi FR, et al.

    Cureus 2020; (12(9)):e10248 doi:10.7759/cureus.10248.

    PMID: 33042687
  17. 17

    Mycobacterium abscessus Pulmonary Disease in a Myasthenia Gravis Patient: A Case Report.

    Lu D, Tong SYC, Cruse B, et al.

    Respirology case reports 2025; (13(7)):e70166 doi:10.1002/rcr2.70166.

    PMID: 40661339
  18. 18

    A diagnosis of late-onset Myasthenia gravis unmasked by topical antibiotics.

    Hussain N, Hussain F, Haque D, Chittivelu S

    Journal of community hospital internal medicine perspectives 2018; (8(4)):230-232 doi:10.1080/20009666.2018.1487245.

    PMID: 30181833
  19. 19

    Perianesthetic Implications and Considerations for Myasthenia Gravis.

    Muckler VC, O'Brien JM, Matson SE, Rice AN

    Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses 2019; (34(1)):4-15 doi:10.1016/j.jopan.2018.03.009.

    PMID: 29980408
  20. 20

    Outcomes of myasthenia gravis patients admitted to the Intensive Care Unit: Experience from a tertiary care center in Saudi Arabia.

    Attar A, Alshaikh H, Alharbi G, et al.

    PloS one 2025; (20(7)):e0328648 doi:10.1371/journal.pone.0328648.

    PMID: 40720448
  21. 21

    Occurrence and severity of myasthenic crisis in an unselected Turkish cohort of patients with myasthenia gravis.

    Ozyurt Kose S, Nazli E, Tutkavul K, Gilhus NE

    Frontiers in neurology 2023; (14()):1201451 doi:10.3389/fneur.2023.1201451.

    PMID: 37521306
  22. 22

    Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.

    Johnson S, Katyal N, Narula N, Govindarajan R

    Medical science monitor : international medical journal of experimental and clinical research 2021; (27()):e933296 doi:10.12659/MSM.933296.

    PMID: 34707081
  23. 23

    Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese.

    Lee CY, Lam CL, Pang SY, et al.

    Journal of neuroimmunology 2015; (289()):177-81.

    PMID: 26616888
  24. 24

    Minimal manifestation status and prednisone withdrawal in the MGTX trial.

    Lee I, Kuo HC, Aban IB, et al.

    Neurology 2020; (95(6)):e755-e766 doi:10.1212/WNL.0000000000010031.

    PMID: 32611638
  25. 25

    Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.

    Clifford KM, Hobson-Webb LD, Benatar M, et al.

    Muscle & nerve 2019; (59(4)):404-410 doi:10.1002/mus.26404.

    PMID: 30575980

This page provides daily management and educational information for living with Myasthenia Gravis. Always consult your neurologist before changing medications, managing a symptom flare, or planning a pregnancy.

Stay up to date

Get notified when new research about Myasthenia gravis is published.

No spam. Unsubscribe anytime.